January, 2010 : TxCell appoints Miguel Forte Chief Medical Officer
July, 2009 : The collaboration project with TxCell, TcLand, INSERM U844/CHRU Montpellier, has been approuved by the French Public Institutions for the development of Tr1 cell-based technology in Rheumatoid Arthritis and Juvenile Idiopathic Arthritis. May 5, 2009 : TxCell opened a new center of investigation for its Phase I/IIa clinical trial. 
January 25-27, 2010Phacilitate Cell & Gene Therapy Forum 2010
The Grand Hyatt,Washington, US
More information here
|
New approach in immunosuppressive strategies Txcell strategy is to develop investigational products in a new class of autologous cellular immunotherapies that are uniquely designed to regulate the patient's own immune system. Autologous cellular immunotherapies hold promise because they may provide patients meaningful clinical benefits with low toxicity. TxCell develops innovative treatments for Crohn's (phase I/IIa) and Rheumatoid Arthritis patients (pre-clinical stage). TxCell is a spin-off from the French Medical Research Institute (INSERM) . |
|
|
|
